Evidence map›Paper›PMID 31134377›Full record

Observational studyJournal of neurology2019

Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.

Leonardo Lopiano, Nicola Modugno, Pietro Marano, Mariachiara Sensi, Giuseppe Meco, Paolo Solla, Graziano Gusmaroli, Filippo Tamma, Francesca Mancini, Rocco Quatrale and 6 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021
    Pooled it
  3. Pooled it
  4. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2021
    Trial
  5. Trial
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Subcutaneous administration of foslevodopa/foscarbidopa (PRODUODOPANeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  14. Review
  15. Monotherapy with infusion therapies - useful or not?Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  16. Article
  17. Article
  18. Current and novel infusion therapies for patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  19. Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Leonardo LopianoDepartment of Neuroscience, University of Torino, Torino, Italy.
Nicola ModugnoIRCCS "Neuromed", Pozzilli, Italy.
Pietro MaranoCasa Di Cura Madonna del Rosario, Raggruppamento Di Riabilitazione, Catania, Italy.
Mariachiara SensiNeurology Unit, Azienda Ospedaliera Universitaria Sant'Anna, Cona, Ferrara, Italy.
Giuseppe MecoDepartment of Neurology and Psychiatry (Parkinson's Centre), Research Centre of Social Diseases (CIMS), Sapienza University, Rome, Italy.
Paolo SollaNeurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy.
Graziano GusmaroliNeurology Unit, Ospedale degli Infermi, Biella, Italy.
Filippo TammaNeurology Unit, Miulli Hospital, Acquaviva delle Fonti, BA, Italy.
Francesca ManciniUO Neurologia e Stroke-Unit e Laboratorio Neuroscienze, Istituto Auxologico San Luca, Milano, Italy.
Rocco QuatraleNeurology Unit, Hospital Dell'Angelo, Mestre, VE, Italy.
Roberta ZangagliaParkinson's Disease and Movement Disorders Unit, IRCCS Neurological National Institute C. Mondino, Pavia, Italy.
Annarita BentivoglioInstitute of Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
Roberto EleopraFondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy.
Giuliana GualbertiAbbVie Srl, Campoverde, LT, Italy.
Gabriella MelziAbbVie Srl, Campoverde, LT, Italy. gabriella.melzi@abbvie.com.ORCID http://orcid.org/0000-0001-9944-3810
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.

Funding

AbbVie Italy NA
6 · The paper itself

Abstract

introductionThe GREENFIELD observational study assessed the effect of levodopa/carbidopa intestinal gel (LCIG) on motor and non-motor symptoms, and the related impact on patient quality of life and caregiver burden up to 8 years.

methodsFinal results of a large Italian cohort of patients who started LCIG in routine care between 2007 and 2014 are presented. Comparison between baseline (before LCIG) and follow-up visits on yearly basis (visit 2/3) is reported. Primary endpoint was Unified Parkinson's Disease Rating Scale (UPDRS-IV) Item 39; secondary endpoints were UPDRS I and II, dyskinesia items, PD Quality of Life Questionnaire-39, Parkinson's Disease Sleep Scale-2, Gait and Falls Questionnaire, Questionnaire on Impulsive Disorders, and Relative Stress Scale.

resultsOverall, 145 patients from 14 centers were assessed with a mean time since LCIG start of 2.8 ± 1.7 years at visit 2. The mean UPDRS-IV item 39 score showed significant reductions compared to baseline (mean score 2.0 ± 0.81) at visit 2 (mean score 0.9 ± 0.69; - 55%; p < 0.001) and at visit 3 (mean score 1.0 ± 0.75; - 50%; p < 0.001). At visit 3, significant reductions were observed for dyskinesia duration score (- 28%; p < 0.001), dyskinesia disability (- 40%; p < 0.001), and painful dyskinesia (- 50%; p < 0.001). Overall, 40 (27.6%) patients experienced 49 serious adverse events which were considered related to PEG/J procedure or to device in 16.3% of the cases.

conclusionsThe results of this study support the long-term efficacy of LCIG on PD symptoms as well as on activities of daily living. The adverse events were consistent with the established LCIG safety profile.

Indexed as

Infusion PumpsAgedAged, 80 and overAntiparkinson AgentsCarbidopaCohort StudiesDrug CombinationsFemaleFollow-Up StudiesGastrostomyGelsHumansItalyJejunumLevodopaMaleAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsGelsLevodopaAdvanced Parkinson’s diseaseIntestinal infusionLevodopa/carbidopaMotor symptomsQuality of lifeRoutine patient care

Identifiers

PMID31134377
PMCPMC6687881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.